stock-detail (GHDX)

Oncology Corporate Profile

Company Description

This company does not have any commercial products

This company does not have any pipeline products

Recent News Headlines

After Negative PET, Drop Bleomycin in Hodgkin's Lymphoma

6/23/2016 10:05 am

(Medscape Medical News) June 22, 2016 - A response-adapted approach to the treatment of patients with advanced Hodgkin's lymphoma de-escalates treatment after an early negative PET scan and intensifies treatment in those with a PET-positive scan — those with the highest risk for treatment failure.

Monday at ASCO: Helping Patients to Help Themselves

6/6/2016 02:00 pm

(Medscape Medical News) June 6, 2016 - News released today at the annual meeting of the American Society of Clinical Oncology shows how lung cancer patients equipped with a smartphone helped themselves to live longer and better.

Immunotherapy Effective Against Some Types of Sarcoma

6/5/2016 06:03 pm

(UPMC) June 5, 2016 - An existing cancer immunotherapy drug reduces tumor size in some types of rare connective tissue cancers, called sarcomas, report researchers at the University of Pittsburgh Cancer Institute (UPCI). Additional analyses of tumor biopsies and blood samples, which will help the researchers better understand which sarcoma subtypes will benefit most from the new treatment, are underway.

Increased Travel Burden Associated with Decreased Likelihood of Receiving Radiation Therapy to Treat Rectal Cancer

3/21/2016 11:03 am

(ASTRO) Mar 21, 2016 - Increased travel distance to a cancer treatment facility negatively impacts the likelihood that patients with stage II/III rectal cancer will receive radiation therapy (RT) to treat their disease, according to a new study.

ASCO to Hold Capitol Hill Briefing March 15 on The State of Cancer Care in America: 2016

3/3/2016 11:04 am

(ASCO) Mar 2, 2016 - The State of Cancer Care in America: 2016 report, to be released on March 15 by the American Society of Clinical Oncology (ASCO), chronicles the current realities of the cancer care delivery system in the United States and examines trends in the oncology workforce and practice environment that are affecting patient care and access.

NICE Turns Down Janssen's Imbruvica For CLL

3/2/2016 11:04 am

(PharmaTimes [UK]) Mar 2, 2016 - Patients with chronic lymphocytic leukaemia (CLL) living in England and Wales are unlikely to get access to Janssen UK’s Imbruvica on the NHS after the drug was turned down by cost regulators.

Breast Cancer and Thyroid: Women With Overactive Thyroid Need To Be Extra Cautious

2/12/2016 11:04 am

(International Business Times) Feb 12, 2016 - The study, published in European Journal of Endocrinology, reveals how hyperthyroid women are 11 percent more likely to develop breast cancer, and women with hypothyroidism are 6 percent less likely to develop the cancer.

Sanofi's Combination Diabetes Drug Hits Goal In Late-Stage Trial

7/29/2015 12:01 pm

(Reuters) July 29, 2015 - Sanofi said on Wednesday a first late-stage Phase III study of its LixiLan diabetes drug had met its main target, while another would be completed at the end of the third quarter.

Bavarian Nordic Announces Initiation of NCI-sponsored Phase 2 Study of PROSTVAC in Patients with Localized Prostate Cancer

7/24/2015 11:02 am

(Bavarian Nordic) July 24, 2015 - Bavarian Nordic A/S announced today that the first patient has been enrolled in a new phase 2 clinical study of PROSTVAC, the Company's active prostate cancer immunotherapy candidate.

Novartis Says Lung Cancer Drug Zykadia Gains EU Approval

5/8/2015 06:02 am

(Reuters) May 8, 2015 - Swiss drugmaker Novartis said European health regulators have approved a drug for advanced lung cancer that is intended to treat patients with a specific genetic mutation.

Physical Exercise Helps Women with Breast Cancer to Better Tolerate Chemotherapy

4/28/2015 11:05 am

(Netherlands Cancer Institute [Amsterdam]) Apr 28, 2015 - Women with breast cancer who follow a physical exercise program during their chemotherapy treatment experience less side effects like fatigue, reduced physical fitness, nausea and pain.

House Passes Boehner-Pelosi Medicare Deal in Resounding Vote

3/26/2015 12:04 pm

(The Hill) Mar 26, 2015 - The House on Thursday overwhelmingly voted to repeal automatic cuts to doctors under Medicare, endorsing a rare bipartisan deal that Speaker John Boehner (R-Ohio) negotiated with Democrats.

Anthem, Cigna to Help Obama Add Value to U.S. Medical Billing

3/25/2015 12:03 pm

(Bloomberg) Mar 25, 2015 - President Barack Obama is enlisting private companies into his drive to change the way the U.S. pays its medical bills, including insurers Anthem Inc. and Cigna Inc. and casino chain Caesars Entertainment Corp.

$10 Copy of Gilead Blockbuster Sovaldi Appears in Bangladesh

3/9/2015 12:00 pm

(Bloomberg) Mar 8, 2015 - A $10 version of Sovaldi, the Gilead Sciences Inc. hepatitis C treatment that sells for $1,000 a pill in the U.S., is now available in Bangladesh and could make its way to other parts of the world where the U.S. company doesn’t have patents.

Tolero Pharmaceuticals Receives EMA Orphan Drug Designation For Alvocidib For the Treatment of Acute Myeloid Leukemia

2/26/2015 12:01 pm

(The Business Journals) Feb 25, 2015 - Tolero Pharmaceuticals, Inc., a clinical-stage company developing treatments for serious hematological diseases, today announced that the European Medicines Agency (EMA) has granted orphan drug designation for alvocidib for the treatment of patients with acute myeloid leukemia (AML).

Raleigh Drug Co. to Relaunch Cancer Pain Medication; Shares Bounce

1/28/2015 12:01 pm

(Triangle Business Journal) Jan 27, 2015 - BioDelivery will re-launch breakthrough cancer pain medicine Onsolis in the United States and find a new partner for the drug, ideally returning more revenue.

Express Scripts Sees Opportunity to Lower Cancer Treatment Cost

1/14/2015 07:00 am

(Reuters) Jan 13, 2015 - Express Scripts, the largest U.S. pharmacy benefit manager, on Tuesday said cost savings on expensive cancer treatments could be achieved if the company were involved earlier in the decision-making process.

Pharma and Docs Up in Arms Over Cancer Drugs Fund Cuts

1/8/2015 07:00 am

(PharmaTimes [UK]) Jan 8, 2015 - The list of drugs to be cut from the Cancer Drugs Fund has yet to be confirmed but drugmakers and doctors have already gone public with their criticisms.

Treatment For Relapsed Multiple Myeloma Patients Guided by FoundationOne® Heme Results in Promising Clinical Activity

12/8/2014 05:03 pm

(TheStreet) Dec 8, 2014 – Foundation Medicine, Inc. today announced new data demonstrating that its comprehensive genomic profile, FoundationOne® Heme, identified genomic alterations in patients with heavily pre-treated multiple myeloma that informed treatment with trametinib, an FDA-approved targeted therapeutic agent.

HPV Vaccine Uptake Among Girls is Lowest in States With Highest Rates of Cervical Cancer

11/12/2014 06:00 am

(AACR) Nov 11, 2014 - The proportion of adolescent girls receiving human papillomavirus (HPV) vaccines was much lower in states with higher rates of cervical cancer incidence and mortality, according to new data.

Rutgers Receives $10 Million Donation for Cancer Research

9/9/2014 07:02 am

(NJ.com) Sept 9, 2014 - Rutgers University has received a $10 million anonymous grant to help its scientists discover targeted therapies for hard-to-treat cancers.

Novartis Hands Over Experimental TB Drugs in Antibiotic Pullback

8/20/2014 07:02 am

(Reuters) Aug 20, 2014 - Novartis has signed a licensing deal to hand over its experimental tuberculosis (TB) drugs to the Global Alliance for TB Drug Development, joining a growing Big Pharma retreat from antibiotics.

CMS Fixes Tech Glitch That Hobbled Pharma Payment Disclosures

8/15/2014 07:04 am

(Wall Street Journal/Pharmalot blog) Aug 14, 2014 - The federal government is back online with a website where U.S. doctors and teaching hospitals can review information about payments they have received from drug and device makers, about 11 days after a government agency shut it down to investigate a data mix-up.

Genomic Health Announces Positive Topline Results of Additional, Large Independent Validation Study of Oncotype DX(R) Prostate Cancer Test with Multiple Clinical Endpoints

8/6/2014 07:00 am

(Genomic Health) Aug 6, 2014 - Genomic Health, Inc. today announced positive preliminary results from an additional independent clinical validation study conducted by the Center for Prostate Disease Research (CPDR) demonstrating that the Oncotype DX® Genomic Prostate Score (GPS) predicts multiple clinical endpoints related to disease aggressiveness in men with low- and intermediate-risk prostate cancer.

Sanofi Cholesterol Drug Meets Main Goal of 9 Trials

7/30/2014 07:01 am

(BloombergBusinessWeek) July 30, 2014 - Sanofi and Regeneron Pharmaceuticals Inc.’s cholesterol drug cut levels of the artery-clogging protein in nine trials, and reduced the rate of heart attack, stroke and death in one test, as the companies race with Amgen Inc. to get a new treatment to market.